

Participant Baseline Characteristics by Treatment Group  
All Participants as Treated

	Placebo		Low Dose		High Dose		Total	
	n	(%)	n	(%)	n	(%)	n	(%)
Participants in population	86		84		84		254	
<b>Age</b>								
<65	14	(16.28)	8	(9.52)	11	(13.10)	33	(12.99)
>80	30	(34.88)	29	(34.52)	18	(21.43)	77	(30.31)
65-80	42	(48.84)	47	(55.95)	55	(65.48)	144	(56.69)
Mean	75.2		75.7		74.4		75.1	
SD	8.6		8.3		7.9		8.2	
SE	0.9		0.9		0.9		0.5	
Median	76.0		77.5		76.0		77.0	
Q1 to Q3	69.25 to 81.75		71 to 82		70.75 to 80		70 to 81	
Range	52 to 89		51 to 88		56 to 88		51 to 89	
<b>Sex</b>								
F	53	(61.63)	50	(59.52)	40	(47.62)	143	(56.30)
M	33	(38.37)	34	(40.48)	44	(52.38)	111	(43.70)
<b>Race</b>								
AMERICAN INDIAN OR ALASKA NATIVE	0	(0.00)	0	(0.00)	1	(1.19)	1	(0.39)
BLACK OR AFRICAN AMERICAN	8	(9.30)	6	(7.14)	9	(10.71)	23	(9.06)
WHITE	78	(90.70)	78	(92.86)	74	(88.10)	230	(90.55)
SD=Standard deviation; SE=Standard error; Q1=First quartile, Q3=Third quartile.								

Source: [CDISCpilot: adam-adsl]